
| Pair Name | Piceatannol, Everolimus | ||
| Phytochemical Name | Piceatannol (PubChem CID: 667639 ) | ||
| Anticancer drug Name | Everolimus (PubChem CID: 6442177 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Piceatannol, Everolimus | |||
| Disease Info | [ICD-11: 2B72.Z] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Down-regulation | Phosphorylation | BECN1 | hsa8678 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | SQSTM1 | hsa8878 | |
| Up-regulation | Expression | BAX | hsa581 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| In Vivo Model | 2×10⁶ SGC7901 cells were resuspended in phosphate-buffered saline (PBS) containing 50% Matrigel and engrafted subcutaneously into each flank of the mice. | |||
| Result | The findings of this study strongly support the application of combinatorial piceatannol and everolimus therapy in future clinical trials for gastric cancer patients. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer. Sci China Life Sci. 2023 Feb;66(2):298-312. doi: 10.1007/s11427-022-2185-9. | Click |